Modifier and HCPCS Changes for October 2024 - JF Part B
Modifier and HCPCS Changes for October 2024
The following new and deleted National Level II modifiers and Healthcare Common Procedure Coding System (HCPCS) are effective for dates of service on/after October 1, 2024.
In compliance with the Health Insurance Portability and Accountability Act (HIPAA), CMS eliminated the 3-month grace period for discontinued codes in Change Request (CR) 3093 dated February 6, 2004. Effective for dates of services on/after January 1, 2010, there is no grace period for billing discontinued HCPCS codes.
Note: The inclusion of modifiers or codes on this web page do not necessarily indicate coverage. New modifiers and HCPCS identified as Durable Medical Equipment (DME) are not included in this listing.
New Modifiers
There are no new modifiers being implemented.
New Codes
| HCPCS | DESCRIPTION |
|---|---|
| A2027 | Matriderm, per square centimeter |
| A2028 | Micromatrix flex, per mg |
| A2029 | Mirotract wound matrix sheet, per cubic centimeter |
| A9610 | Xenon xe-129 hyperpolarized gas, diagnostic, per study dose |
| C8000 | Support device, extravascular, for arteriovenous fistula (implantable) |
| C9169 | Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram |
| C9170 | Injection, tarlatamab-dlle, 1 mg |
| C9171 | Injection, pegulicianine, 1 mg |
| C9172 | Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose |
| J0138 | Injection, acetaminophen 10 mg and ibuprofen 3 mg |
| J1171 | Injection, hydromorphone, 0.1 mg |
| J1749 | Injection, iloprost, 0.1 mcg |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg |
| J2003 | Injection, lidocaine hydrochloride, 1 mg |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg |
| J2252 | Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg |
| J2253 | Injection, midazolam (seizalam), 1 mg |
| J2601 | Injection, vasopressin (baxter), 1 unit |
| J8522 | Capecitabine, oral, 50 mg |
| J8541 | Dexamethasone (hemady), oral, 0.25 mg |
| J9329 | Injection, tislelizumab-jsgr, 1mg |
| P9027 | Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit |
| Q0519 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days |
| Q0520 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days |
| Q4334 | Amnioplast 1, per square centimeter |
| Q4335 | Amnioplast 2, per square centimeter |
| Q4336 | Artacent c, per square centimeter |
| Q4337 | Artacent trident, per square centimeter |
| Q4338 | Artacent velos, per square centimeter |
| Q4339 | Artacent vericlen, per square centimeter |
| Q4340 | Simpligraft, per square centimeter |
| Q4341 | Simplimax, per square centimeter |
| Q4342 | Theramend, per square centimeter |
| Q4343 | Dermacyte ac matrix amniotic membrane allograft, per square centimeter |
| Q4344 | Tri-membrane wrap, per square centimeter |
| Q4345 | Matrix hd allograft dermis, per square centimeter |
| Q5135 | Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg |
| Q5136 | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg |
Deleted Codes
| HCPCS | DESCRIPTION |
|---|---|
| C9150 | Xenon xe-129 hyperpolarized gas, diagnostic, per study dose |
| J1170 | Injection, hydromorphone, up to 4 mg |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg |
| J8520 | Capecitabine, oral, 150 mg |
| J8521 | Capecitabine, oral, 500 mg |
| J9258 | Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg |
Source
- Transmittal 12655, CR 13575 dated May 23, 2024
Last Updated Sep 16 , 2024
